Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France

Applied Health Economics and Health Policy

Volumn 11, Issue 3, 2013, Pages 205-218

  Pichetti, Sylvain ^a   Sermet, Catherine ^a   Godman, Brian ^b,c,d   Campbell, Stephen M ^e   Gustafsson, Lars L ^b  

^a IRDES   (France)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CONSULTATION; DIABETES MELLITUS; DISORDERS OF LIPOPROTEIN METABOLISM; FEMALE; FRANCE; GENERAL PRACTITIONER; HEART DISEASE; HUMAN; MALE; MEDICAL FEE; MULTILEVEL ANALYSIS; PHYSICIAN ATTITUDE; PRESCRIPTION; PROBABILITY; WORKLOAD;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DIABETES MELLITUS; DRUG PRESCRIPTIONS; DRUGS, GENERIC; FATTY ACIDS, MONOUNSATURATED; FEMALE; FLUOROBENZENES; FRANCE; GENERAL PRACTITIONERS; HEART DISEASES; HEPTANOIC ACIDS; HUMANS; INDOLES; LIPID METABOLISM DISORDERS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PHYSICIAN'S PRACTICE PATTERNS; PRAVASTATIN; PRESCRIPTION DRUGS; PYRIMIDINES; PYRROLES; SIMVASTATIN; SULFONAMIDES;

EID: 84878758624     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0014-4     Document Type: Article

References (69)

1. Sermet C, Andrieu V, Godman B, et al. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy. 2010;8(1):7-24.
2. Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoecon Outcomes Res. 2008;8(4):357-71.
3. Wettermark B, Godman B, Andersson K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics. 2008;26(7):537-50.
4. Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(6):707-22.
5. Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in europe: findings and future implications. Front Pharmacol. 2010;1:141.
6. Godman B, Malmstrom RE, Bennie M, et al. Prescribing restrictions - a necessary strategy among some European countries to enhance future prescribing efficiency? Rev Health Care. 2012;3:5-16.
7. Garattini S, Bertele' V, Godman B, et al. Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol. 2008;64(12):1137-8.
8. Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9(1):65-83.
9. McGinn D, Godman B, Lonsdale J, et al. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(1):73-85.
10. Godman B, Shrank W, Wettermark B, et al. Use of generics - a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals. 2010;3:2470-94.
11. Garuoliene K, Godman B, Gulbinovic J, et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11(3):343-9.
12. Coma A, Zara C, Godman B, et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev Pharmacoecon Outcomes Res. 2009;9(6):569-81.
13. Godman B, Wettermark B, Bishop I, et al. European payer initiatives to reduce prescribing costs through use of generics. GABI. 2012;1:22-7.
14. Pettersson B, Hoffmann M, Wandell P, et al. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy. 2012;104(1):84-91.
15. Vrijens F, Van de Voorde C, Farfan-Portet MI et al. Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data. Eur J Health Econ. 2012; 13(3):315-325.
16. Wettermark B, Godman B, Neovius M, et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy. 2010;94(3):221-9.
17. Wettermark B, Pehrsson A, Juhasz-Haverinen M, et al. Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care. Qual Prim Care. 2009;17(3):179-89.
18. Gustafsson LL, Wettermark B, Godman B, et al. The 'wise list' - a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108(4):224-33.
19. Martikainen JE, Saastamoinen LK, Korhonen MJ, et al. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care. 2010;48(9):761-6.
20. Voncina L, Strizrep T, Godman B, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):469-79.
21. Godman B, Sakshaug S, Berg C, et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11(1):121-9.
22. Sjoborg B, Backstrom T, Arvidsson LB, et al. Design and implementation of a point-of-care computerized system for drug therapy in Stockholm metropolitan health region-Bridging the gap between knowledge and practice. Int J Med Inform. 2007;76(7):497-506.
23. Ostini R, Hegney D, Jackson C, et al. Systematic review of interventions to improve prescribing. Ann Pharmacother. 2009;43(3):502-13.
24. Freemantle N. Implementation strategies. Fam Pract. 2000;17(Suppl 1):S7-10.
25. O'Brien MA, Rogers S, Jamtvedt G et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2007;(4):CD000409.
26. Wettermark B, Godman B, Jacobsson B, et al. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Appl Health Econ Health Policy. 2009;7(3):137-47.
27. Godman B, Abuelkhair M, Vitry A, et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GABI. 2012;1(2):69-83.
28. Cour des Comptes. Rapport annuel sur la sécurité sociale. La maîtrise des dépenses de médicaments 2010. 2011. Available at http://www.ccomptes.fr/Publications/Publications/Securite-sociale- 2011. Accessed 18 Mar 2013.
29. Godman B, Paterson K, Malmstrom RE, et al. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):439-41.
30. Convention nationale organisant les rapports entre les médecins libéraux et l'Assurance maladie JORF n 0223 du 25 septembre 2011, page 16080 texte n 16.
31. Weng TC, Yang YH, Lin SJ, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139-51.
32. Norman C, Zarrinkoub R, Hasselstrom J, et al. Potential savings without compromising the quality of care. Int J Clin Pract. 2009;63(9):1320-6.
33. Usher-Smith J, Ramsbottom T, Pearmain H, et al. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract. 2008;62(3):480-4.
34. Boh M, Opolski G, Poredos P, et al. Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk. Int Angiol. 2011;30(4):366-74.
35. French National Authority for Health. Efficacité et efficience des hypolipémiants: une analyse centrée sur les statines. 2012. Available at http://www.has-sante.fr/portail/upload/docs/application/pdf/2010- 09/5-statines-argumentaire-complet-maj-sept-2010.pdf. Accessed 18 Mar 2013.
36. Bennie M, Godman B, Bishop I, et al. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):125-30.
37. Bejean S, Peyron C, Urbinelli R. Variations in activity and practice patterns: a French study for GPs. Eur J Health Econ. 2007;8(3):225-36.
38. Davis P, Gribben B, Lay-Yee R, et al. How much variation in clinical activity is there between general practitioners? A multi-level analysis of decision-making in primary care. J Health Serv Res Policy. 2002;7(4):202-8.
39. Steffensen FH, Sorensen HT, Olesen F. Diffusion of new drugs in Danish general practice. Fam Pract. 1999;16(4):407-13.
40. Tamblyn R, McLeod P, Hanley JA, et al. Physician and practice characteristics associated with the early utilization of new prescription drugs. Med Care. 2003;41(8):895-908.
41. Tollen L. Physician organization in relation to quality and efficiency of care. A synthesis of recent literature. 2008. Kaiser Permanente Institute for Health Policy, the Commonwealth Fund.
42. Mehrotra A, Epstein AM, Rosenthal MB. Do integrated medical groups provide higher-quality medical care than individual practice associations? Ann Intern Med. 2006;145(11):826-33.
43. Wong IC, Murray ML, Camilleri-Novak D, et al. Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child. 2004;89(12):1131-2.
44. Pichetti S, Sorasith C, Sermet C. Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: a time-series analysis for France 1998-2010. Health Policy. 2011;102(2-3):159-69.
45. Paterson L, Goldstein H. New statistical methods for analysing social structures: an introduction to multilevel models. British Educational Res J. 1991;17:387-93.
46. Geleedst-De VM, Maitland-van der Zee AH, Schalekamp T et al. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study. Drugs Aging. 2010; 27(7):589-596.
47. Heck R, Thomas S. An introduction of multilevel modelling technics. New York: Routledge; 1999.
48. Raudenbush S, Bryk A. Hierarchical linear models. Applications and data analysis methods. SAGE Publications Inc.: Osborne; 2002.
49. Pfeffermann D, Skinner CJ, Holmes DJ, et al. Weighting for unequal selection probabilities in multilevel models. J R Stat Soc Ser B (statistical methodology). 1998;60(1):23-40.
50. Templeton L, Deehan A, Taylor C, et al. Surveying general practitioners: does a low response rate matter? Br J Gen Pract. 1997;47(415):91-4.
51. Hummers-Pradier E, Scheidt-Nave C, Martin H, et al. Simply no time? Barriers to GPs' participation in primary health care research. Fam Pract. 2008;25(2):105-12.
52. Grande D, Frosch DL, Perkins AW, et al. Effect of exposure to small pharmaceutical promotional items on treatment preferences. Arch Intern Med. 2009;169(9):887-93.
53. Kyle GJ, Nissen LM, Tett SE. Pharmaceutical company influences on medication prescribing and their potential impact on quality use of medicines. J Clin Pharm Ther. 2008;33(5):553-9.
54. Fischer MA, Keough ME, Baril JL, et al. Prescribers and pharmaceutical representatives: why are we still meeting? J Gen Intern Med. 2009;24(7):795-801.
55. Greving JP, Denig P, van der Veen WJ, et al. Determinants for the adoption of angiotensin II receptor blockers by general practitioners. Soc Sci Med. 2006;63(11):2890-8.
56. Prosser H, Almond S, Walley T. Influences on GPs' decision to prescribe new drugs-the importance of who says what. Fam Pract. 2003;20(1):61-8.
57. Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ. 2001;323(7309):378-81.
58. Tobin L, de Almedia Neto AC, Wutzke S et al. Influences on the prescribing of new drugs. Aust Fam Physician. 2008; 37(1-2): 78-80, 83.
59. Watkins C, Moore L, Harvey I, et al. Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study. BMJ. 2003;326(7400):1178-9.
60. Prosser H, Walley T. New drug uptake: qualitative comparison of high and low prescribing GPs' attitudes and approach. Fam Pract. 2003;20(5):583-91.
61. Plans-Rubio P. The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices. Am J Cardiovasc Drugs. 2010;10(6):369-82.
62. Voncina L, Strizrep T. Croatia 2009/2010. Pharmaceutical pricing and reimbursement reform. Eurohealth. 2011;16:20-2.
63. Mousques J, Renaud T, Scemama O. Is the "practice style" hypothesis relevant for general practitioners? An analysis of antibiotics prescription for acute rhinopharyngitis. Soc Sci Med. 2010;70(8):1176-84.
64. Bras PL, Ricordeau P, Roussille B et al. GP's information on medicines. L'information des médecins généralistes sur le médicament. Rapport de l'IGAS, September 2007.
65. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730-40.
66. Green CJ, Maclure M, Fortin PM et al. Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane Database Syst Rev 2010; (8):CD008654.
67. Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998;317(7156):465-8.
68. Barton S. Using clinical evidence. BMJ. 2001;322(7285):503-4.
69. Abernethy D, Birkett D, Brosen K, Cascorbi I, Gustafsson LL, Hoppu K, Maxwll S, Orme M, Rago L, Rawlin M Sir, Reidenberg M, Sjöqvist F, Smith T, Thuerman P, Walubo A. Clinical pharmacology in health care, teaching and research. Joint publication by WHO, CIOMS and IUPHAR (International Union of Pharmacology and Clinical Pharmacology) edited by Orme M, Sjöqvist F and Birkett D, Geneva 2012, Oct 8. Available at www.cioms.ch/index.php/component/ booklibrary/?task=view&Itemid=&id=46&catid=58. Accessed 18 Jan 2013.